Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ITGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsInteger agrees to $5.7B all-cash KKR buyout at $127/share; Q2 sales down 2.6%
Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read
Key Changes
-
high
KKR to acquire Integer for $127/share in cash, valuing the enterprise at $5.7 billion. Shareholders receive a substantial premium to recent trading levels; Integer will become a private company.
Exhibit 99.1 view on EDGAR → -
high
Integer withdrew all financial guidance and canceled its earnings call due to the pending transaction, standard practice when entering a definitive merger agreement.
Exhibit 99.1 view on EDGAR → -
medium
Q2 2026 sales fell 2.6% to $464 million (organic down 1.5%). GAAP EPS from continuing operations dropped 34% to $0.69; adjusted EPS rose 3% to $1.60.
Exhibit 99.1 view on EDGAR → -
medium
Cardio & Vascular sales declined 2% to $280 million due to impacts from two new Electrophysiology products. Cardiac Rhythm Management & Neuromodulation grew 1% to $174 million despite one new Neuromodulation product headwind.
Exhibit 99.1 view on EDGAR → -
low
Total debt increased $53 million to $1.238 billion; leverage ratio stood at 3.2x adjusted EBITDA as of July 3, 2026.
Exhibit 99.1 view on EDGAR →
Summary
Integer Holdings announced it has entered into a definitive agreement to be acquired by KKR in an all-cash transaction valued at $5.7 billion. Shareholders will receive $127 per share in cash, representing a substantial premium to recent trading levels. The company will become privately held under KKR investment funds.
Integer withdrew all previously issued financial guidance and canceled its scheduled earnings call, standard practice when a definitive merger agreement is signed. The company also reported Q2 2026 results showing sales down 2.6% to $464 million, with organic sales declining 1.5%. GAAP diluted EPS from continuing operations fell 34% to $0.69, while adjusted EPS rose 3% to $1.60.
The divergence reflects higher restructuring and other charges in the GAAP results. Cardio & Vascular sales declined 2% due to impacts from two new Electrophysiology products, while Cardiac Rhythm Management & Neuromodulation grew 1% despite headwinds from one new Neuromodulation product. For shareholders, the KKR transaction represents a liquidity event at a premium valuation. The quarterly results are now secondary to the pending acquisition, which will determine the ultimate return for current holders.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Cardio & Vascular sales decreased 2% to $280 million in the second quarter 2026 compared to the second quarter 2025, reflecting the previously communicated impact from the two new Electrophysiology products.
Cardiac Rhythm Management & Neuromodulation sales increased 1% to $174 million in the second quarter 2026 compared to the second quarter 2025. Growth was partially offset by the previously communicated impact from the one new Neuromodulation product.
Other Markets sales totaled $10 million in the second quarter 2026, compared to $18 million in the second quarter 2025, primarily due to the Portable Medical exit.
Cardio & Vascular sales fell 2% to $280 million due to impacts from two new Electrophysiology products. Cardiac Rhythm Management & Neuromodulation sales grew 1% to $174 million despite headwinds from one new Neuromodulation product. Other Markets sales dropped to $10 million from $18 million, primarily reflecting the strategic exit of the Portable Medical business.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify